ArticleScientific reports2024
Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Targeting progressive multiple sclerosis: Toward mechanism-informed precision medicine.Journal of internal medicine · 2026Review
- Designing and conducting interventional trials with passive-sensing applications on patient-owned smartphones: challenges and recommendations from the BD4QoL study.Frontiers in digital health · 2026Article
- Trust and anxiety as primary drivers of digital health acceptance in multiple sclerosis: toward an extended disease-specific technology acceptance model.Frontiers in digital health · 2026Article
- From lesion detection to outcome prediction: artificial intelligence and deep learning applications in multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Sensors in Multiple Sclerosis.Current neurology and neuroscience reports · 2025Review
- Review
- Artificial Intelligence-Driven Neuromodulation in Neurodegenerative Disease: Precision in Chaos, Learning in Loss.Biomedicines · 2025Review
- Longitudinal Digital Phenotyping of Multiple Sclerosis Severity Using Passively Sensed Behaviors and Ecological Momentary Assessments: Real-World Evaluation.Journal of medical Internet research · 2025Article
- Investigating Measurement Equivalence of Smartphone Sensor-Based Assessments: Remote, Digital, Bring-Your-Own-Device Study.Journal of medical Internet research · 2025Article
- Smartphone postural sway and pronator drift tests as measures of neurological disability.BMC neurology · 2025Article
- From implementation to discontinuation: multi-year experience with the multiple sclerosis performance test as a digital monitoring tool.Frontiers in digital health · 2025Article
- [Digital health apps : How to achieve the successful integration into healthcare].Innere Medizin (Heidelberg, Germany) · 2024Review
- Smartphone Postural Sway and Pronator Drift tests as Measures of Neurological Disability.medRxiv : the preprint server for health sciences · 2024Article
- Assessing disease progression and treatment response in progressive multiple sclerosis.Nature reviews. Neurology · 2024Review
- User Experience of a Large-Scale Smartphone-Based Observational Study in Multiple Sclerosis: Global, Open-Access, Digital-Only Study.JMIR human factors · 2024Observational
- Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.Journal of neurology · 2024Article
- The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event.Frontiers in neurology · 2024Review
- The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics.Therapeutic advances in neurological disorders · 2024Article
- Cost-effectiveness of the FloodlightDigital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Floodlight Open was a global, open-access, digital-only study designed to understand the drivers and barriers in deployment and use of a smartphone app in a naturalistic setting and broad study population of people with and without multiple sclerosis (MS). The study utilised the Floodlight Open app: a 'bring-your-own-device' solution that remotely measures a user's mood, cognition, hand motor function, and gait and postural stability via smartphone sensor-based tests requiring active user input ('active tests'). Levels of mobility of study participants ('life-space measurement') were passively measured. Study data from these tests were made available via an open-access platform. Data from 1350 participants with self-declared MS and 1133 participants with self-declared non-MS from 17 countries across four continents were included in this report. Overall, MS participants provided active test data for a mean duration of 5.6 weeks or a mean duration of 19 non-consecutive days. This duration increased among MS participants who persisted beyond the first week to a mean of 10.3 weeks or 36.5 non-consecutive days. Passively collected life-space measurement data were generated by MS participants for a mean duration of 9.8 weeks or 50.6 non-consecutive days. This duration increased to 16.3 weeks/85.1 non-consecutive days among MS participants who persisted beyond the first week. Older age, self-declared MS disease status, and clinical supervision as part of concomitant clinical research were all significantly associated with higher persistence of the use of the Floodlight Open app. MS participants performed significantly worse than non-MS participants on four out of seven active tests. The findings from this multinational study inform future research to improve the dynamics of persistence of use of digital monitoring tools and further highlight challenges and opportunities in applying them to support MS clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.